*This chart includes clinical trials of therapeutics that are sponsored by industry. It was updated through March of 2021. For a complete list of all clinical trials impacted by COVID-19, see Cortellis.

Company	Product	Indication	Details	Date announced
Clinical trials disrupted: 442
89bio Inc., of San Francisco	BIO89-100	Nonalcoholic steatohepatitis	Initiation of phase IIb trial of the FGF receptor agonist now expected in first half of 2021, delayed from first half of 2020, due to COVID-19 pandemic	4/13/20
AB Science SA, of Paris	Masitinib	Amyotrophic lateral sclerosis	FDA cleared the IND for a phase III study (AB19001); confirmatory phase III study set to start enrollment once post-COVID-19 pandemic conditions permit proper access sites, which may delay the enrollment date initially planned in March 2020 by up to 3 months; mastinib is a selective tyrosine kinase inhibitor	3/31/20
AB Science SA, of Paris	Masitinib	Mastocytosis	Confirmatory phase III study set to start enrollment once post-COVID-19 pandemic conditions permit proper access sites, which may delay the enrollment date initially planned in March 2020 by up to 3 months; mastinib is a selective tyrosine kinase inhibitor	4/7/20
Actelion Ltd., of Allschwil, Switzerland	Uptravi (selexipag)	Pulmonary arterial hypertension	Study in healthy volunteers suspended due to COVID-19	4/22/20
Actelion Ltd., of Allschwil, Switzerland	Uptravi (selexipag)	Pulmonary arterial hypertension	Screening in study to confirm doses in children with PAH on hold due to COVID-19	5/12/20
Actelion Ltd., of Allschwil, Switzerland	Uptravi (selexipag)	Chronic thromboembolic pulmonary hypertension	Screening temporarily halted in Select study due to COVID-19	5/13/20
Addex Therapeutics Ltd., of Geneva	Dirpaglurant	Parkinson's disease	Ready to begin pivotal phase IIb/III study in patients with levodopa-induced dyskinesia as soon as the COVID-19 pandemic is over; dosing first patient in second half of 2020 will result in data in the second quarter of 2022; dipraglurant is a metabotropic glutamate receptor 5 antagonist	4/8/20
Addex Therapeutics, of Geneva	Dipraglurant	Levodopa-induced dyskinesia in patients with Parkinson's disease	Postponing the start of the registrational efficacy and safety trial, Study 301, as the intended patient population is among the highest risk category for severe illness and death associated with COVID-19; dipraglurant is a novel orally available mGlu5 NAM	3/18/20
Adial Pharmaceuticals Inc., of Charlottesville, Va.	AD-04	Alcohol use disorder	Modifying its pivotal phase III trial to protect patients from COVID-19 by reducing the number of in-person visits to clinical sites and using tele-medicine behavioral treatments and assessments	3/17/20
Aeglea Biotherapeutics Inc., of Austin, Texas	Pegzilarginase	Arginase 1 deficiency	Disclosed in SEC filing that COVID-19 has created limited access environment, impacting the ability for some sites in Peace study to schedule and complete initial screening visits; company now expects to complete enrollment by end of March 2021 and anticipates top-line data in fourth quarter of 2021; to date, 22 patients (75%) have been enrolled	1/5/21
Agios Pharmaceuticals Inc., of Cambridge, Mass.	AG-270	Non-small-cell lung and pancreatic cancers	Enrollment slowed due to COVID-19; go/no-go decision still expected no later than 2022	4/30/20
Agios Pharmaceuticals Inc., of Cambridge, Mass.	Mitapivat	Sickle cell disease	Enrollment paused due to COVID-19	4/30/20
Agios Pharmaceuticals Inc., of Cambridge, Mass.	Tibsovo (ivosidenib)	Myelodysplastic syndrome	Enrollment completion now expected in 2021 vs. previous guidance of end of 2020, due to COVID-19-related delays	4/30/20
Agios Pharmaceuticals Inc., of Cambridge, Mass.	Vorasidenib	Low-grade glioma	Enrollment in Indigo study slowed due to COVID-19	4/30/20
Aldeyra Therapeutics Inc., of Lexington, Mass.	ADX-2191	Proliferative vitreoretinopathy	Patient enrollment in part 1 of adaptive Guard trial for prevention of PVR significantly delayed due to lack of clinical site availability and staffing resulting from COVID-19	5/7/20
Alexion Pharmaceuticals Inc., of Boston	ALXN-1830	Warm autoimmune hemolytic anemia	Study stopped due to COVID-19, as WAIHA patients may be at higher risk of contracting disease based on standard-of-care treatments	5/13/20
Alexion Pharmaceuticals Inc., of Boston	Strensiq (asfotase alfa)	Hypophosphatasia	Study withdrawn after portfolio review and in light of COVID-19 pandemic	6/1/20
Alligator Bioscience AB, of Lund, Sweden	ATOR-1015	Metastatic cancer	Temporarily halted recruitment of new patients due to COVID-19	4/1/20
Alligator Bioscience AB, of Lund, Sweden	ATOR-1017	Metastatic cancer	Temporarily halted recruitment of new patients due to COVID-19	4/1/20
AM Pharma BV, Utrecht, the Netherlands	Recap	Sepsis-associated acute kidney injury	While current hospital resources are focused on COVID-19, AM Pharma intends to move into the phase III trial as soon as circumstances allow	3/31/20
Amag Pharmaceuticals Inc., of Waltham, Mass.	AMAG-423	Pre-eclampsia	Site initiation and enrollment in phase IIb/IIIa trial of the ovine antidigoxin polyclonal antibody fragment expected to be delayed by COVID-19 pandemic	4/16/20
Amag Pharmaceuticals Inc., of Waltham, Mass.	Ciraparantag	Anticoagulant overdose	Site initiation and enrollment in phase IIb trial of the factor IIa/Xa modulator in healthy volunteers expected to be delayed by COVID-19 pandemic	4/16/20
Aprea Therapeutics Inc., of Boston	APR-246	HMA-naïve TP53 mutant myelodysplastic syndromes	Company has observed a decrease in patient screening and enrollment in the phase III trial as a result of COVID-19	3/26/20
Aptinyx Inc., of Evanston, Ill.	NYX-2925	Diabetic peripheral neuropathy	Restarted recruitment and screening following a suspension due to the COVID-19 pandemic	1/4/21
Argenx NV, of Breda, the Netherlands	Cusatuzumab (ARGX-110)	Acute myeloid leukemia	Partner Janssen Pharmaceuticals paused enrollment of pivotal Culminate trial, testing combination with azacitidine in newly diagnosed elderly patients unfit for intensive chemotherapy, due to COVID-19	5/14/20
Aridis Pharmaceuticals Inc., of San Jose, Calif.	AR-301 (tosatoxumab)	Ventilator-associated pneumonia	Enrollment and site activation affected by COVID-19 pandemic; interim data of the human IgG1 monoclonal antibody provisionally expected in second half of 2020 and top-line data in second half of 2021	4/9/20
Ark Biosciences Inc., of Shanghai	Ziresovir; AK-3280	Respiratory syncytial virus; idiopathic pulmonary fibrosis	Ark CEO said the company had to pause some of its clinical studies because research associates could not get to the hospitals due to the COVID-19 pandemic	3/27/20
Arrowhead Pharmaceuticals Inc., of Pasadena, Calif.	ARO-AAT	Alpha-1 liver disease	Pausing new patient screening for at least a four-week period in the Sequoia and Aroaat2002 studies as many patients have compromised lung function and/or impaired liver function and are at increased risk for COVID-19; patients already enrolled will continue in the study as per the protocol, with options including home healthcare visits and the use of local laboratories; ARO-AAT is designed to knock down the hepatic production of the mutant alpha-1 antitrypsin protein	3/17/20
Aslan Pharmaceuticals Ltd., of Singapore	ASLAN-004	Atopic dermatitis	Recruitment of the IL-13/IL-4 receptor antagonist in multiple ascending-dose study enrolling adults with moderate to severe disease paused due to COVID-19 pandemic; screening expected to resume in May 2020, with interim unblinded data still expected to report in 2020	4/13/20
Astellas Pharma Inc., of Tokyo	ASP-1617	Unspecified	Study assessing food effect in healthy adult non-Asian and Japanese subjects suspended due to COVID-19	5/15/20
Astellas Pharma Inc., of Tokyo	ASP-2390	House dust mite allergy	Study suspended due to COVID-19	5/15/20
Astellas Pharma Inc., of Tokyo	Fezolinetant	Unspecified	Trial assessing bioequivalence of fezolinetant formulations in postmenopausal women suspended due to COVID-19	5/15/20
Astex Pharmaceuticals Inc., of Pleasanton, Calif., a subsidiary of Otsuka Pharmaceutical Co. Ltd., and Forma Therapeutics Inc., of Watertown, Mass.	ASTX-727 and FT-2102	Recurrent/refractory myelodysplastic syndrome of acute myeloid leukemia	Phase I/II study in patients with IDHI-mutated disease paused due to COVID-19	5/20/20
Astrazeneca plc, of Cambridge, U.K.	AZD-9977	Heart failure with preserved ejection fraction	Study to compare effect of AZD-9977 and spironolactone on serum potassium in HFpEF patients terminated; attendance at study sites carries risk of COVID-19 infection, and non-attendance deemed unacceptable patient safety risk	5/1/20
Astrazeneca plc, of Cambridge, U.K.	Budesonide and Formoterol via two different inhalers	Chronic obstructive pulmonary disease	Phase III trial put on hold due to the COVID-19 pandemic	4/8/20
Astrazeneca plc, of Cambridge, U.K.	Olaparib	Prostate cancer	Phase II study temporarily suspended due to COVID-19	3/31/20
Astrazeneca plc, of Cambridge, U.K.	Vinorelbine	Advanced solid tumors	Suspended phase I/II Movie trial testing combination with anti-PD-L1/anti-CTLA4 immunotherapy due to COVID-19	4/20/20
Atara Biotherapeutics Inc., of South San Francisco	ATA-188	Progressive multiple sclerosis	Temporarily paused screening and enrollment of patients in phase Ib study due to COVID-19; company expects pause to be limited and plans to initiate enrollment in second or third quarter of 2020	5/7/20
Atara Biotherapeutics Inc., of South San Francisco	ATA-188	Multiple sclerosis	Monitoring of enrolled participants and retreatment in open-label extension of phase Ia continue; screening and enrollment of phase Ib participants paused due to COVID-19 pandemic; Autologous cytotoxic T-lymphocyte therapy	4/2/20
Auris Medical Holding Ltd., of Hamilton, Bermuda	AM-125	Acute peripheral vertigo	Resumed enrollment in study that was paused due to COVID-19; interim analysis expected in the third quarter of 2020	5/26/20
Auris Medical Holding Ltd., of Hamilton, Bermuda	AM-125 (betahistine, intranasal)	Acute peripheral vertigo	Enrollment in Travers phase II trial halted in March 2020 after sites reduced or suspended research activities due to COVID-19 pandemic; interim analysis following part A of trial now expected no sooner than third quarter of 2020	4/6/20
Autifony Therapeutics Ltd., of Stevenage, U.K.	AUT0-0201	Schizophrenia; hearing disorders	Single and multiple ascending-dose trial underway in U.K. in healthy volunteers suspended temporarily due to COVID-19 pandemic	5/4/20
Aveo Oncology Inc., of Cambridge, Mass.	Ficlatuzumab	Relapsed/refractory acute myeloid leukemia	CyFi-2 phase II study discontinued due to COVID-19 pandemic	3/30/20
Avrobio Inc., of Cambridge, Mass.	AVR-RD-02	Gaucher disease	First patient enrolled and completed apheresis in phase I/II study, and dosing is anticipated for the second quarter but is dependent on when the clinical site allows; subsequent new enrollment timelines impacted by COVID-19	5/7/20
Avrobio Inc., of Cambridge, Mass.	AVR-RD-04	Cystinosis	Patient identification activities ongoing in phase I/II study, though certain data collection temporarily delayed due to COVID-19	5/7/20
Axsome Therapeutics Inc., of New York	AXS-05 (dextromethorphan/bupropion)	Alzheimer's disease agitation	Accelerating completion of the Advance-1 phase II/III trial of the oral NMDA receptor antagonist; randomization have concluded and trial participation is ending to ensure patient safety during COVID-19; topline results are expected early in the second quarter, instead of the third quarter of 2020	3/20/20
Azevan Pharmaceuticals Inc., of Bethlehem, Pa.	SRX-246	Post traumatic stress disorder	Study suspended due to COVID-19	6/18/20
Bayer AG, of Leverkusen, Germany	Azelastine hydrochloride (BAYR-9258)	Allergic rhinitis	Suspended due to COVID-19	5/18/20
Bellicum Pharmaceuticals Inc., of Houston	Rivogenlecleucel donor lymphocyte immunotherapy	Recurrent blood cancers after stem cell transplant	Recruitment of phase I trial temporarily discontinued due to COVID-19	4/10/20
Bellus Health Inc., of Laval, Quebec	BLU-5397	Unexplained or refractory chronic cough	Terminated due to impact of COVID-19 on trial activities	4/29/20
Bellus Health Inc., of Laval, Quebec	BLU-5937	Refractory chronic cough	Completed dosing of 52 patients in the Relief study of the P2X3 receptor antagonist; 16 patients dropped out of the study, including 13 due to COVID-19 pandemic or early termination of the trial; data expected in mid-2020	4/7/20
Belx Bio-Pharmaceutical (Taiwan) Corp., of Taiwan	Bel-X-HG	Advanced cancer	Terminated in light of ongoing COVID-19 pandemic, which resulted in difficulty with patient enrollment	6/1/20
Bergenbio ASA, of Bergen, Norway	Bemcentinib	Lung cancer and leukemia	Measures taken to reduce the spread of COVID-19 are expected to impact patient recruitment in Bergenbio's clinical studies, including the phase II trial, and will extend previously anticipated timelines	3/27/20
Bicycle Therapeutics plc, of Cambridge, U.K.	BT-1718	Solid tumors	Enrollment of new patients in phase IIa portion of trial at Cancer Research UK sites paused due to the COVID-19 pandemic	5/7/20
Bicycle Therapeutics plc, of Cambridge, U.K.	BT-8009	Advanced solid tumors associated with Nectin-4 expression	Plans to start a phase I clinical trial of the peptide-toxin conjugate targeting Nectin-4 this year, subject to impact of COVID-19 pandemic	4/7/20
Bioarctic AB, of Stockholm, and Eisai Co. Ltd., of Tokyo	Lecanemab (BAN-2401)	Alzheimer's disease	Target enrollment number increased by about 200 in pivotal Clarity AD trial in people with early disease to ensure robust dataset and mitigate potential impact of missed doses due to COVID-19 pandemic; data readout still expected by September 2022	2/3/21
Biogen Inc., of Cambridge, Mass.	BIIB-067 (tofersen)	Motor neuron disease	Healthy volunteer study testing microdose of radiolabeled BIIB-067 (99mTc-MAG3-BIIB067) co-administered with BIIB-067 on hold due to COVID-19	5/12/20
Bionic Sight LLC, of New York	BS-01 (optogenetic gene therapy)	Retinitis pigmentosa	First participant dosed in phase I/II trial assessing effectiveness to detect light, motion and shape/object recognition; application of therapy to subsequent participants postponed due to COVID-19 pandemic, with enrollment set to resume in second half of 2020	6/16/20
Biontech SE, of Mainz, Germany	HPV anti-CD40 RNA vaccine	HPV16+ head and neck cancer	Phase I study suspended due to COVID-19	3/26/20
Biontech SE, of Mainz, Germany	NEO-PV-01	Advanced melanoma	Study testing product, either with APX-005M (Apexigen Therapeutics Inc.) or Opdivo (nivolumab, Bristol Myers Squibb Co.) in patients with advanced or metastatic disease closed due to historically slow enrollment compounded by COVID-19 pandemic	9/4/20
Blade Therapeutics Inc., of South San Francisco	BLD-2660	Idiopathic pulmonary fibrosis	Suspended due to concerns for patient safety during COVID-19 crisis	9/3/20
Blueberry Therapeutics Ltd., of Macclesfield, U.K.	BB-2603	Onychomycosis	Study paused due to COVID-19 pandemic impact	11/10/20
Bluebird Bio Inc., of Cambridge, Mass.	bb-21217	Multiple myeloma	Shifting the timing of enrollment and completion of ongoing studies by at least three months; studies remain open, but the COVID-19 pandemic are resulting in disruptions to study conduct	3/26/20
Bluebird Bio Inc., of Cambridge, Mass.	FH-MCVA2TCR autologous T cells	Metastatic or unresectable Merkel cell cancer	Phase I/II study suspended due to COVID-19	4/21/20
Bluebird Bio Inc., of Cambridge, Mass.	lenti-D	Cerebral adrenoleukodystrophy	Shifting the timing of enrollment and completion of ongoing studies by at least three months; studies remain open, but the COVID-19 pandemic are resulting in disruptions to study conduct	3/26/20
Bluebird Bio Inc., of Cambridge, Mass.	Lentiglobin	Beta-thalassemia and sickle cell disease	Shifting the timing of enrollment and completion of ongoing studies by at least three months; studies remain open, but the COVID-19 pandemic are resulting in disruptions to study conduct; rolling BLA submission to the FDA for lentiglobin will not be complete until mid-2021	3/26/20
Boehringer Ingelheim GmbH, of Ingelheim, Germany	Afatinib	Pediatric tumors	Recruitment in phase I/II study temporarily halted due to COVID-19	4/21/20
Boehringer Ingelheim GmbH, of Ingelheim, Germany	BI-1265162	Healthy subjects	Recruitment of phase I trial discontinued due to COVID-19	4/7/20
Boehringer Ingelheim GmbH, of Ingelheim, Germany	BI-1265162	Cystic fibrosis	Study testing use of Respimat inhaler suspended due to COVID-19	4/22/20
Boehringer Ingelheim GmbH, of Ingelheim, Germany	BI-1265162 delivered by Respimat inhaler	Cystic fibrosis	Recruitment of phase II trial temporarily discontinued due to the COVID-19 pandemic	4/6/20
Boehringer Ingelheim GmbH, of Ingelheim, Germany	BI-1323495	Healthy subjects	Recruitment of phase I trial temporarily suspended due to the COVID-19 pandemic	4/6/20
Boehringer Ingelheim GmbH, of Ingelheim, Germany	BI-1323495	Healthy subjects	Recruitment of phase I trial discontinued due to COVID-19	4/8/20
Boehringer Ingelheim GmbH, of Ingelheim, Germany	BI-1323495	Chronic obstructive pulmonary disease; cystic fibrosis	Study designed to investigate the relative bioavailabilities of rosuvastatin and dabigatran given alone and together with BI-1323495 to healthy people suspended due to COVID-19	4/24/20
Boehringer Ingelheim GmbH, of Ingelheim, Germany	BI-1387446 alone or in combination with BI-754091	Solid tumors	Recruitment of phase I trial temporarily discontinued due to COVID-19	4/6/20
Boehringer Ingelheim GmbH, of Ingelheim, Germany	BI-1701963 alone and combined with Trametinib	Solid tumors	Recruitment of phase I trial temporarily suspended due to the COVID-19 pandemic	4/7/20
Boehringer Ingelheim GmbH, of Ingelheim, Germany	BI-409306	Attenuated psychosis syndrome	Recruitment of phase II trial temporarily discontinued due to the COVID-19 pandemic	4/7/20
Boehringer Ingelheim GmbH, of Ingelheim, Germany	BI-409306	Schizophrenia	Recruitment of phase II trial temporarily discontinued due to the COVID-19 pandemic	4/6/20
Boehringer Ingelheim GmbH, of Ingelheim, Germany	BI-425809	Schizophrenia	Recruitment of phase II trial temporarily discontinued due to the COVID-19 pandemic	4/7/20
Boehringer Ingelheim GmbH, of Ingelheim, Germany	BI-425809	Schizophrenia	Study testing drug in combination with brain training suspended due to COVID-19	4/22/20
Boehringer Ingelheim GmbH, of Ingelheim, Germany	BI-474121	Healthy subjects	Recruitment of phase I trial temporarily discontinued due to COVID-19	4/7/20
Boehringer Ingelheim GmbH, of Ingelheim, Germany	BI-655130	Fistulizing Crohn's disease	Recruitment of new subjects temporarily discontinued due to COVID-19	4/20/20
Boehringer Ingelheim GmbH, of Ingelheim, Germany	BI-685509	Hepatic impairment	Recruitment of phase I trial temporarily discontinued due to COVID-19	4/9/20
Boehringer Ingelheim GmbH, of Ingelheim, Germany	BI-690517	Diabetic kidney disease	Recruitment of phase I trial temporarily discontinued due to the COVID-19 pandemic	4/7/20
Boehringer Ingelheim GmbH, of Ingelheim, Germany	BI-706321	Healthy subjects	Recruitment of phase I trial temporarily discontinued due to the COVID-19 pandemic	4/6/20
Boehringer Ingelheim GmbH, of Ingelheim, Germany	BI-706321	Unidentified indication	Study designed to investigate safety, tolerability, pharmacokinetics and bioavailability in healthy people suspended due to COVID-19	4/24/20
Boehringer Ingelheim GmbH, of Ingelheim, Germany	BI-730357	Healthy subjects	Recruitment of phase I trial temporarily discontinued due to COVID-19	4/10/20
Boehringer Ingelheim GmbH, of Ingelheim, Germany	BI-754091	Solid tumors	Recruitment of phase I trial temporarily discontinued due to the COVID-19 pandemic	4/7/20
Boehringer Ingelheim GmbH, of Ingelheim, Germany	BI-754091 in combination with other checkpoint inhibitors	Solid tumors	Recruitment of phase II trial temporarily discontinued due to the COVID-19 pandemic	4/6/20
Boehringer Ingelheim GmbH, of Ingelheim, Germany	BI-754091/BI-754111	Neoplasm	Recruitment of phase I trial temporarily discontinued due to COVID-19	4/9/20
Boehringer Ingelheim GmbH, of Ingelheim, Germany	BI-754111	Non-small cell lung cancer or head and neck cancer	Recruitment of phase I trial temporarily discontinued due to the COVID-19 pandemic	4/7/20
Boehringer Ingelheim GmbH, of Ingelheim, Germany	BI-754111 alone or in combination with BI-754091	Non-small cell lung cancer	Recruitment of phase I trial temporarily discontinued due to the COVID-19 pandemic	4/7/20
Boehringer Ingelheim GmbH, of Ingelheim, Germany	BI-754132	Age-related macular degeneration	Recruitment of phase I trial temporarily discontinued due to the COVID-19 pandemic	4/7/20
Boehringer Ingelheim GmbH, of Ingelheim, Germany	BI-764198	Healthy subjects	Recruitment of phase I trial temporarily discontinued due to the COVID-19 pandemic	4/7/20
Boehringer Ingelheim GmbH, of Ingelheim, Germany	BI-836880	Wet macular degeneration	Recruitment of phase I trial temporarily discontinued due to the COVID-19 pandemic	4/7/20
Boehringer Ingelheim GmbH, of Ingelheim, Germany	BI-836880 alone and in combination with BI-754091	Solid tumors	Recruitment of phase I trial temporarily discontinued due to the COVID-19 pandemic	4/7/20
Boehringer Ingelheim GmbH, of Ingelheim, Germany	BI-836880 in combination with BI-754091	Non-small cell lung cancer	Recruitment of phase I trial temporarily discontinued due to the COVID-19 pandemic	4/6/20
Boehringer Ingelheim GmbH, of Ingelheim, Germany	BI-891065 alone and in combination with BI-754091	Solid tumors	Recruitment of phase I trial temporarily suspended due to the COVID-19 pandemic	4/7/20
Boehringer Ingelheim GmbH, of Ingelheim, Germany	BI-894416	Healthy subjects	Recruitment of phase I trial temporarily discontinued due to COVID-19	4/7/20
Boehringer Ingelheim GmbH, of Ingelheim, Germany	BI-894416	Asthma	Study designed to investigate safety, tolerability, pharmacokinetics and bioavailability in healthy people suspended due to COVID-19	4/24/20
Boehringer Ingelheim GmbH, of Ingelheim, Germany	BI-905677	Solid tumors	Recruitment of phase I trial temporarily discontinued due to the COVID-19 pandemic	4/6/20
Boehringer Ingelheim GmbH, of Ingelheim, Germany	BI-905681	Neoplasm	Recruitment of phase I trial temporarily discontinued due to COVID-19	4/7/20
Boehringer Ingelheim GmbH, of Ingelheim, Germany	BI-905711	Gastrointestinal cancer	Recruitment of phase I trial temporarily suspended due to the COVID-19 pandemic	4/7/20
Boehringer Ingelheim GmbH, of Ingelheim, Germany	BI-907828	Solid tumors	Recruitment of phase I trial temporarily discontinued due to the COVID-19 pandemic	4/7/20
Boehringer Ingelheim GmbH, of Ingelheim, Germany	BI-907828 in combination with BI-754091 and BI-754111	Solid tumors	Recruitment of phase I trial temporarily discontinued due to the COVID-19 pandemic	4/22/20
Boehringer Ingelheim GmbH, of Ingelheim, Germany	BI-907828; BI-754091; BI-754111	Solid tumors	Suspended due to COVID-19 pandemic	4/22/20
Boehringer Ingelheim GmbH, of Ingelheim, Germany	Idarucizumab	Atrial fibrillation	Recruitment of phase III trial temporarily discontinued due to the COVID-19 pandemic	4/22/20
Boehringer Ingelheim GmbH, of Ingelheim, Germany	Idarucizumab	Bleeding	Recruitment of new patients who take dabigatran and need emergency surgery or are bleeding suspended due to COVID-19	4/22/20
Boehringer Ingelheim GmbH, of Ingelheim, Germany	Linagliptin and empagliflozin	Type 2 diabetes	Halted recruitment of new children and adolescents due to COVID-19	4/21/20
Boehringer Ingelheim GmbH, of Ingelheim, Germany	Nintedanib	Idiopathic pulmonary fibrosis	Study in patients for pulmonary rehabilitation IPF suspended due to COVID-19	4/21/20
Boehringer Ingelheim GmbH, of Ingelheim, Germany	Nintedanib	Interstitial lung disease	Recruitment of phase III trial temporarily suspended due to the COVID-19 pandemic	4/7/20
Boehringer Ingelheim GmbH, of Ingelheim, Germany	Tiotropium + olodaterol	Chronic obstructive pulmonary disease	Recruitment of phase IV trial temporarily paused due to the COVID-19 pandemic	4/7/20
Boehringer Ingelheim GmbH, of Ingelheim, Germany	Xentuzumab	Solid tumors	Study aiming to find safe dose in combination with abemaciclib, with or without hormonal therapies, suspended due to COVID-19	4/22/20
Boehringer Ingelheim GmbH, of Ingelheim, Germany	Xentuzumab in combination with Abemaciclib	Lung and breast cancer	Recruitment of phase I trial temporarily discontinued due to the COVID-19 pandemic	4/22/20
Boehringer Ingelheim GmbH, of Ingelheim, Germany	Xentuzumab plus Everolimus and Exemestane	Hormone receptor positive and HER2-negative breast cancer	Recruitment of phase II trial temporarily suspended due to the COVID-19 pandemic	4/9/20
Bristol Myers Squibb Co., of New York	Nivolumab plus Relatlimab or Ipilimumab	Metastatic melanoma	Recruitment of phase II trial temporarily suspended due to the COVID-19 pandemic	4/13/20
Bristol Myers Squibb Co., of New York	Opdivo (nivolumab)	High-risk human papillomavirus-related head and neck cancer	Study testing combination with radiotherapy and carboplatin/paclitaxel suspended due to COVID-19	5/1/20
Bristol Myers Squibb Co., of New York	pTVG-HP and Nivolumab	Non-metastatic PSA-recurrent prostate cancer	Phase II study temporarily suspended due to COVID-19	4/1/20
Bristol Myers Squibb Co., of New York	Various drugs	Various indications	Company posted a letter to clinical investigators suspending new site activations for ongoing trials, as of March 20 through April 13 and possibly later; sites for new studies will not be activated globally, and studies involving healthy volunteers should not initiate	3/20/20
Bristol Myers Squibb Co., of New York and Janssen Research & Development LLC, part of New Brunswick, N.J.-based Johnson & Johnson	JNJ-70033093 and Digoxin	Healthy subjects	Recruitment of phase I trial temporarily discontinued due to the COVID-19 pandemic	4/3/20
Cabaletta Bio Inc., of Philadelphia	DSG3-CAART	Mucosal pemphigus vulgaris	Anticipates a delay in reporting the acute safety data from the first cohort in DesCAARTes trial due to COVID-19 pandemic	3/30/20
Cadent Therapeutics Inc., of Cambridge, Mass.	CAD-1883	Spinocerebellar ataxia	Trial initiation delayed due to COVID-19 pandemic	4/29/20
Cadent Therapeutics, of Cambridge, Mass.	CAD-1883	Spinocerebellar ataxia	Phase II trial scheduled to start in August 2020 was suspended due to COVID-19	4/13/20
Calithera Biosciences Inc., of South San Francisco	CB-280	Cystic fibrosis	Enrollment of the arginase inhibitor delayed until third quarter of 2020 due to COVID-19 pandemic	4/14/20
Calithera Biosciences Inc., of South San Francisco	Telaglenastat	Renal cell carcinoma; triple-negative breast cancer	Dose-expansion cohorts in phase I/II combination trial of the glutaminase inhibitor with CDK4/6 inhibitor Ibrance (palbociclib, Pfizer Inc.) and PARP inhibitor Talzenna (talazoparib, Pfizer) paused due to COVID-19 pandemic; enrollment expected to resume in third quarter 2020	4/14/20
Calithera Biosciences Inc., of South San Francisco	Telaglenastat	Colorectal cancer; non-small-cell lung cancer	Dose-expansion cohorts in phase I/II combination trial of the glutaminase inhibitor with CDK4/6 inhibitor Ibrance (palbociclib, Pfizer Inc.) in KRAS-mutated disease paused due to COVID-19 pandemic; enrollment expected to resume in third quarter 2020	4/14/20
Calithera Biosciences Inc., of South San Francisco	Telaglenastat	Non-small-cell lung cancer	Enrollment of first participant in the phase II Keapsake trial assessing the glutaminase inhibitor in those with NRF2/KEAP1 mutation delayed until third quarter of 2020 due to COVID-19 pandemic; interim data expected in 2021	4/14/20
Cassava Sciences Inc., of Austin, Texas	PTI-125	Alzheimer's disease	Initiated an open-label extension of its phase II, but sites may slow pace of enrollment to minimize risk of exposure to coronavirus	3/25/20
Catalyst Pharmaceuticals Inc., of Coral Gables, Fla.	Firdapse (amifampridine)	Spinal muscular atrophy type III	Proof-of-concept trial fully recruited and screened but not permitted to start due to Serbian government regulations related to COVID-19 pandemic; top-line data will not be reported by end of second quarter; Firdapse is a potassium channel inhibitor	4/8/20
Cindome Pharma LLC, a subsidiary of Cincinnati-based Cinrx Pharma LLC	CIN-102	Diabetic gastroparesis	Terminated due to impact of COVID-19 on trial activities	5/18/20
Cohbar Inc., of Menlo Park, Calif.	CB4-211	Nonalcoholic steatohepatitis	Anticipating delays in the completion of the CB4-211 phase Ib study as a result of a pause by some CRO partners in response to the COVID-19 pandemic	3/30/20
Cumberland Pharmaceuticals Inc., of Nashville, Tennessee	Ifetroban Sodium	Malignant solid tumor	Phase II study paused due to COVID-19	3/30/20
Curis Inc., of Lexington, Mass.	CA-4948	Relapsed or refractory non-Hodgkin lymphoma	Due to COVID-19, certain sites remain open for enrollment while others have temporarily halted enrollment of new patients; company expects to report updated efficacy data from study and declare recommended phase II dose in 2020	5/12/20
Cyclerion Therapeutics Inc., of Cambridge, Mass.	IW-6463	Neurodegenerative disease	Study in healthy elderly participants terminated; some subjects could not complete second crossover period due to COVID-19-related site closure; study closed to allow analysis of all collected data	6/19/20
Cytokinetics Inc., of South San Francisco	CK-274	Hypertrophic cardiomyopathy	Enrollment in the phase II Redwood-HCM study of the myosin inhibitor paused due to COVID-19 pandemic; data from first cohort may be available in second half of 2020 if cohort's enrollment is completed by midyear 2020	4/14/20
Cytokinetics Inc., of South San Francisco, and Amgen Inc., of Thousand Oaks, Calif.	AMG-594	Heart failure	Enrollment in a phase I trial of the cardiac troponin activator is suspended due to COVID-19 pandemic	4/14/20
Cytokinetics Inc., of South San Francisco, and Amgen Inc., of Thousand Oaks, Calif.	Omecamtiv mecarbil	Heart failure	Enrollment in Meteoric-HF phase III trial of the myosin stimulator paused due to COVID-19 pandemic; risk mitigation for enrolled participants includes remote study visits and home delivery of study drug; site startup activities continue, and enrollment of 270 planned participants may be completed by year-end 2020 if enrollment is reactivated by end of second quarter 2020	4/14/20
Cytomx Therapeutics Inc., of South San Francisco	CX-072	Melanoma	Terminating the Proclaim-CX-072-002 study evaluating the PD-L1 probody CX-072 in combination with Yervoy (ipilimumab), following a re-evaluation of the clinical, competitive and commercial landscapes, as well as the impact of COVID-19; the decision frees up resources for other projects	3/31/20
Cytomx Therapeutics Inc., of South San Francisco	CX-2009	Hormone receptor positive HER2 negative breast cancer	Pausing new patient enrollment and new site activation in the Proclaim-CX-2009-001 study evaluating the CD166-targeting probody drug conjugate	3/31/20
Daiichi Sankyo Co. Ltd., of Tokyo	DS-8201a	Advanced breast cancer	Suspended due to COVID-19	4/20/20
Denali Therapeutics Inc., of South San Francisco	DNL-151	Parkinson’s disease	Enrollment in phase I and phase Ib studies paused due to COVID-19; analyzing data from studies; plans to select DNL-151 or DNL-201 for phase II/III development by mid-2020	4/3/20
Denali Therapeutics Inc., of South San Francisco	DNL-310	Hunter syndrome	Phase I study remains on track to start in the second quarter; enrollment in observational biomarker study paused due to COVID-19	4/3/20
Denali Therapeutics Inc., of South San Francisco	DNL-343	Healthy volunteers (eventually amyotrophic lateral sclerosis/frontotemporal degeneration)	Phase I enrollment paused due to COVID-19	4/3/20
Dermira Inc., of Menlo Park, Calif.	Lebrikizumab	Moderate-to-severe atopic dermatitis	Recruitment of phase III trial temporarily suspended due to the COVID-19 pandemic	4/6/20
Dermira Inc., of Menlo Park, Calif.	Lebrikizumab plus topical corticosteroid	Moderate-to-severe atopic dermatitis	Recruitment of phase III trial temporarily suspended due to the COVID-19 pandemic	4/6/20
Desentum Oy, of Espoo, Finland	DM-101	Birch pollen allergy	Recruitment of phase I trial temporarily discontinued due to the COVID-19 pandemic	4/3/20
Destiny Pharma plc, of Brighton, U.K.	XF-73	Prevention of postsurgical infections	Phase IIIb study paused due to COVID-19 pandemic	4/29/20
Dicerna Pharmaceuticals Inc., of Lexington, Mass.	Nedosiran	Primary hyperoxaluria	Due to COVID-19, there has been a temporary suspension of further clinical trial activities at multiple sites and the company no longer expects to complete enrollment in the pivotal trial in the second quarter of 2020	3/27/20
Diffusion Pharmaceuticals Inc., of Charlottesville, Va.	TSC (trans sodium crocetinate)	Acute stroke	Enrollment delay expected in ambulance-based PHAST-TSC trial of the Vitamin A analogue due to COVID-19	3/25/20
Eiger Biopharmaceuticals Inc., of Palo Alto, Calif.	Lonafarnib	Hepatitis delta virus infection	Completion of D-LIVR study enrollment shifted into 2021 due to COVID-19; Farnesyl transferase inhibitor	4/2/20
Eli Lilly and Co., of Indianapolis	LY-3526318	Pain	Study in healthy volunteers terminated due to COVID-19	4/22/20
Eli Lilly and Co., of Indianapolis	Abemaciclib	HR-positive, HER2-negative metastatic breast cancer	Enrolling in study testing combination with fulvestrant vs. chemotherapy on hold due to COVID-19	4/27/20
Eli Lilly and Co., of Indianapolis	Ixekizumab	Plaque psoriasis	Suspended due to COVID-19 pandemic	4/22/20
Eli Lilly and Co., of Indianapolis	LY-2963016	Type 2 diabetes	Study in India suspended due to COVID-19	4/28/20
Eli Lilly and Co., of Indianapolis	LY-3009104 (baricitinib)	Rheumatoid arthritis	Enrollment on hold in Ra-Branch study due to COVID-19	4/28/20
Eli Lilly and Co., of Indianapolis	LY-3009104 (baricitinib)	Active JIA-associated uveitis or chronic anterior antinuclear antibody-positive uveitis	Enrollment on hold due to COVID-19	4/28/20
Eli Lilly and Co., of Indianapolis	LY-3305677	Type 2 diabetes	Suspended due to COVID-19 pandemic	4/22/20
Eli Lilly and Co., of Indianapolis	LY-3361237	Systemic lupus erythematosus	Suspended due to COVID-19 pandemic	4/22/20
Eli Lilly and Co., of Indianapolis	LY-3372689	Alzheimer's disease	Enrollment of healthy volunteers suspended due to COVID-19	4/22/20
Eli Lilly and Co., of Indianapolis	LY-3454738	Atopic dermatitis	Suspended enrollment due to COVID-19	4/22/20
Eli Lilly and Co., of Indianapolis	LY-3454738	Chronic spontaneous urticaria	Enrollment on hold due to COVID-19	4/27/20
Eli Lilly and Co., of Indianapolis	LY-3462817	Psoriasis	Enrollment on hold due to COVID-19	4/22/20
Eli Lilly and Co., of Indianapolis	LY-3463251	Diabetes	Enrollment of healthy volunteers suspended due to COVID-19	4/22/20
Eli Lilly and Co., of Indianapolis	LY-3471851	Psoriasis	Enrollment on hold due to COVID-19	4/22/20
Eli Lilly and Co., of Indianapolis	LY-3471851	Eczema	Enrollment on hold due to COVID-19	4/22/20
Eli Lilly and Co., of Indianapolis	LY-3475070	Advanced cancer	Enrollment in study testing combination with Keytruda (pembrolizumab, Merck & Co. Inc.) on hold due to COVID-19	4/22/20
Eli Lilly and Co., of Indianapolis	LY-3475766	Cardiovascular disease	Enrollment of healthy volunteers suspended due to COVID-19	4/22/20
Eli Lilly and Co., of Indianapolis	LY-3478045	Endocrine/metabolic diseases	Enrollment of healthy volunteers suspended due to COVID-19	4/22/20
Eli Lilly and Co., of Indianapolis	LY-3499446	Advanced solid tumors	Enrollment in phase I/II trial of patients with KRAS G12C mutation on hold due to COVID-19	4/22/20
Eli Lilly and Co., of Indianapolis	LY-3502970	Endocrine/metabolic disorders	Trial in healthy volunteers suspended due to COVID-19	5/1/20
Eli Lilly and Co., of Indianapolis	LY-3556050	Pain	Enrollment of healthy volunteers suspended due to COVID-19	4/22/20
Eli Lilly and Co., of Indianapolis	LY-900014	Type 2 diabetes	Enrollment in study comparing drug to Humalog suspended due to COVID-19	6/5/20
Eli Lilly and Co., of Indianapolis	LY-900014	Type 1 diabetes	Suspended due to COVID-19 pandemic	4/22/20
Eli Lilly and Co., of Indianapolis	Tirzepatide	Type 2 diabetes	Enrollment in contraceptive pharmacokinetics study in healthy female volunteers halted due to COVID-19	4/22/20
Eli Lilly and Co., of Indianapolis	Tirzepatide	Impaired liver function	Suspended due to COVID-19 pandemic	4/22/20
Eli Lilly and Co., of Indianapolis	Trulicity (dulaglutide)	Type 2 diabetes	New 36-week data from Award-11 trial showed higher doses (3 mg and 4.5 mg) were well-tolerated and led to A1C reduction up to 1.9% and weight reduction up to 10.4 pounds	5/8/20
Eli Lilly and Co., of Indianapolis	Various drugs	Various indications	Lilly said it is delaying most of its new clinical trial starts and pausing enrollment in most of its ongoing studies while continuing those for patients who are already enrolled; the move is to focus on COVID-19 R&D and easing the burden on health care facilities	3/23/20
Eloxx Pharmaceuticals Inc., of Waltham, Mass.	ELX-02	Cystic fibrosis	Enrollment in phase II program temporarily paused due to COVID-19 pandemic; ELX-02 is a CFTR gene modulator	3/25/20
Enanta Pharmaceuticals Inc., of Watertown, Mass.	EDP-305	Non-alcoholic steatohepatitis	In response to the COVID-19 pandemic, it has paused recruitment and dosing in its Argon-2 phase IIb NASH study	3/27/20
Enanta Pharmaceuticals Inc., of Watertown, Mass.	EDP-514	Hepatitis B virus	In response to the COVID-19 pandemic, it has paused recruitment in part 2 of a phase Ia/Ib study in nuc-suppressed hepatitis B patients	3/27/20
Endo Pharmaceuticals plc, of Dublin	Collagenase Clostridium histolyticum (EN-3835)	Cellulite	Phase IIa study testing CCH in buttock and thigh cellulite in adult women temporarily suspended due to COVID-19 disruptions	7/28/20
Equillium Inc., of La Jolla, Calif.	EQ-001 (itolizumab)	Asthma; lupus nephritis	To protect patients, caregivers and employees, company has paused enrollment in the Equip trial for uncontrolled asthma and the Equalise trial for lupus nephritis; itolizumab is a monoclonal antibody that targets the CD6-ALCAM pathway	3/26/20
Exelixis Inc., of Alameda, Calif.	Cabozantinib	Prostate cancer	Trial testing drug followed by prostatectomy in high-risk patients suspended due to COVID-19	4/22/20
Ferring Pharmaceuticals SA, of Saint-Prex, Switzerland	FE-999049 + GnRH agonist	Infertility	Recruitment of phase III trial temporarily discontinued due to the COVID-19 pandemic	3/24/20
Ferring Pharmaceuticals SA, of Saint-Prex, Switzerland	Menopur	Infertility	Recruitment of phase III trial temporarily discontinued due to the COVID-19 pandemic	3/24/20
Ferring Pharmaceuticals SA, of Saint-Prex, Switzerland	Quinagolide vaginal ring	Endometriosis-related pain	Recruitment of phase II trial temporarily halted due to the COVID-19 pandemic	3/31/20
Ferring Pharmaceuticals SA, of Saint-Prex, Switzerland	Quinagolide vaginal ring	Endometriosis	Recruitment of phase II trial temporarily halted due to the COVID-19 pandemic	4/7/20
Flexion Therapeutics Inc., of Burlington, Mass.	FX-201	Osteoarthritis of the knee	Suspending the phase I study temporarily to ensure the safety of trial participants during the COVID-19 pandemic	4/1/20
Flexion Therapeutics Inc., of Burlington, Mass.	Zilretta	Shoulder osteoarthritis or adhesive capsulitis	Suspending the phase II trial temporarily to ensure patient safety during the COVID-19 pandemic	4/1/20
Forty Seven Inc., of Menlo Park, Calif.	FSI-174	Hematologic cancer	Start of the phase I trial of the cKIT tyrosine kinase inhibitor in healthy volunteers id delayed due to COVID-19	3/20/20
Fulcrum Therapeutics Inc., of Cambridge, Mass.	Losmapimod	Facioscapulohumeral muscular dystrophy	Phase IIb Redux4 trial of the p38 alpha/beta MAP kinase inhibitor is fully enrolled but trial activity suspended at many sites due to COVID-19 pandemic; top-line data for primary endpoint of change from baseline in DUX4 activity may not be available by end of third quarter of 2020, as planned	4/2/20
Galecto Inc., of Boston	GB-1211	Nonalcoholic steatohepatitis and liver fibrosis	Phase I/II trial withdrawn due to COVID-19 pandemic and change in clinical development strategy for compound	2/4/21
Galmed Pharmaceuticals Inc., of Tel Aviv, Israel	Aramchol	Nonalcoholic steatohepatitis and fibrosis	Decided to temporarily halt screening of new patients for phase III/IV Armor study due to COVID-19, and aims to resume activity on a country by country, state by state and site by site basis as conditions improve	5/14/20
Genentech, of South San Francisco, a unit of the Roche Group	Carboplatin with or without Atezolizumab	Stage iv triple negative breast cancer	Recruitment of phase II trial temporarily suspended due to the COVID-19 pandemic	4/13/20
Genentech, of South San Francisco, a unit of the Roche Group	Xolair (omalizumab)	Moderate to severe allergic asthma	Recruitment and screening visits suspended until further notice due to the COVID-19 pandemic	4/17/20
Geneuro SA, of Geneva	Temlimab	Multiple sclerosis	Postponing its planned phase II trial at the Karolinska Institute's Academic Specialist Center in Stockholm to prioritize healthcare resources behind the fight of COVID-19 and to reduce the risk for MS patients	3/19/20
Genfit SA, of Lille, France	Elafibranor	Non-alcoholic steatohepatitis and primary biliary cholangitis	Pausing all phase I trials due to COVID-19; the studies are necessary to support the NDA submission for NASH; enrollment of patients in the pharmacokinetic and pharmacodynamic trial in pediatric patients with NASH and the phase II study addressing liver fat have also been paused; has also put on hold the start of a phase II combination study and a phase III study in patients with	3/31/20
Gensight Biologics SA, of Paris	GS-030	Retinitis pigmentosa	Recruitment of third cohort of 3 participants to receive maximal dose of the channel rhodopsin gene stimulator delayed due to COVID-19 pandemic but expected to complete in second half of 2020	4/14/20
Geron Corp., of Menlo Park, Calif.	Imetelstat	Myelodysplastic syndrome and acute myelogenous leukemia	Due to COVID-19, company does not expect to complete enrollment in the Imerge phase III trial or to begin the proof-of-concept study in high-risk MDS and AML by the end of 2020, as originally planned	4/2/20
Geron Corp., of Menlo Park, Calif.	Imetelstat	Lower-risk myelodysplastic syndromes	Due to effects of COVID-19 pandemic on site initiations and enrollment, patient enrollment now expected to complete by end of first quarter of 2021, with top-line results expected in second half of 2022	5/22/20
Glaxosmithkline plc, of London	Belimumab	Kidney transplant	Phase I study suspended due to COVID-19	3/27/20
Glaxosmithkline plc, of London	Bexsero	Meningococcal disease	Study, in infants 6 weeks through 12 months of age, when administered with pneumococcal conjugate vaccine, has temporarily suspended recruitment activities due to the COVID-19 pandemic	4/17/20
Glaxosmithkline plc, of London	Clostridium difficile vaccine based on the F2 antigen	Clostridium difficile infection	Recruitment of phase I trial temporarily suspended due to the COVID-19 pandemic	4/13/20
Glaxosmithkline plc, of London	Daprodustat	Anemia	Recruitment of phase I trial temporarily suspended due to COVID-19	4/14/20
Glaxosmithkline plc, of London	Daprodustat	Anemia in chronic kidney disease	Recruitment in study comparing effect of drug to darbepoetin alfa on endothelial function by assessing forearm blood flow temporarily paused due to COVID-19	5/4/20
Glaxosmithkline plc, of London	Dolutegravir/lamivudine	Therapy-naive HIV-infected adolescents	Recruitment suspended due to COVID-19 pandemic	4/17/20
Glaxosmithkline plc, of London	GSK-1437173A	Herpes Zoster	Recruitment of phase III trial temporarily suspended due to the COVID-19 pandemic	4/13/20
Glaxosmithkline plc, of London	GSK-1437173A	Shingles in children with kidney transplant	Recruitment of phase II trial temporarily suspended due to the COVID-19 pandemic	4/13/20
Glaxosmithkline plc, of London	GSK-3036656	Drug-sensitive pulmonary tuberculosis	Recruitment activities suspended due to COVID-19	4/22/20
Glaxosmithkline plc, of London	GSK-3196165 (otilimab)	Rheumatoid arthritis	Study testing drug vs. placebo and sarilumab in patients with moderately to severely active disease who have inadequate response to disease-modifying therapy and/or JAK inhibitors temporarily suspended recruitment due to COVID-19	4/28/20
Glaxosmithkline plc, of London	GSK-3196165 (otilimab)	Rheumatoid arthritis	Study testing drug vs. placebo tofacitinib in patients with moderately to severely active disease who have inadequate response to methotrexate temporarily suspended recruitment due to COVID-19	4/28/20
Glaxosmithkline plc, of London	GSK-3858279	Pain	Recruitment activities in study testing battery of evoked pain tests in healthy volunteers temporarily suspended due to COVID-19	5/25/20
Glaxosmithkline plc, of London	GSK-3858279	Osteoarthritis	Recruitment suspended due to COVID-19, though other elements of study are ongoing	4/24/20
Glaxosmithkline plc, of London	HBV (Hepatitis B Virus) viral vector vaccines and adjuvanted proteins vaccine (GSK3528869A)	Hepatitis B virus infection	Recruitment of phase I trial temporarily suspended due to COVID-19	4/13/20
Glaxosmithkline plc, of London	Mepolizumab	Chronic obstructive pulmonary disease	Recruitment of phase III trial temporarily suspended due to the COVID-19 pandemic	4/8/20
Glaxosmithkline plc, of London	RSVPreF3 vaccine	Respiratory syncytial virus infections	Recruitment of phase II trial temporarily suspended due to the COVID-19 pandemic	4/13/20
Glycomimetics Inc., of Rockville, MD.	Uproleselan	Relapsed/refractory acute myeloid leukemia	Reported in first-quarter earnings that site initiation, recruitment and enrollment slowed in April due to COVID-19	5/1/20
Gossamer Bio Inc., of San Diego	GB-002	Pulmonary arterial hypertension	Given COVID-19-related delays in enrollment, company now anticipates reporting initial results from phase Ib trial in second half of 2020	5/12/20
GT Biopharma Inc., of Beverly Hills, Calif.	GTB-3550	CD33+ malignancies	Restarted enrollment in phase I/II study after a 30-day pause due to the COVID-19 pandemic	1/12/21
Helix Biopharma Corp., of Richmond Hill, Ontario	L-DOS47	Pancreatic cancer	Phase Ib/II study (LDOS006) testing combination with doxorubicin continues to enroll and has dosed 2 patients; however, given the COVID-19 pandemic, company expects patient enrollment will be impacted; immuno-conjugate drug	4/2/20
Hookipa Pharma Inc., of New York and Vienna	HB-101	Cytomegalovirus	Due to COVID-19 pandemic, nearly all ongoing trial sites have suspended patient enrollment; it remains unclear when kidney organ transplants will resume at any of the sites	5/14/20
Ico Therapeutics Inc., of Vancouver, British Columbia	ICO-019 (amphotericin B, oral)	Infection	Start of phase II trial of the macrolide antibiotic delayed due to COVID-19 pandemic	4/15/20
Imbrium Therapeutics LP, subsidiary of Purdue Pharma LP, of Stamford, Conn., and Spinethera Inc., of Plymouth, Minn.	V-117957	Insomnia associated with alcohol cessation	Recruitment suspended due to COVID-19	4/20/20
Immunomedics Inc., of Morris Plains, N.J.	Sacituzumab Govitecan	Metastatic solid tumors	Phase II study temporarily suspended due to COVID-19	3/25/20
Immunomedics Inc., of Morris Plains, N.J.	Sacituzumab Govitecan	Metastatic breast cancer	Phase III study temporarily suspended due to COVID-19	3/25/20
Immunomedics Inc., of Morris Plains, N.J.	Sacituzumab Govitecan	Metastatic urothelial cancer	Phase II study temporarily suspended due to COVID-19	3/25/20
Incyte Inc., of Wilmington, Del.	Epacadostat	Locally advanced rectal cancer	Trial adding epacadostat to preoperative chemoradiation suspended due to COVID-19	4/22/20
Incyte Inc., of Wilmington, Del.	Itacitinib	Soft tissue sarcomas	Phase I study temporarily suspended due to COVID-19	3/31/20
Indalo Therapeutics Inc., of Cambridge, Mass.	IDL-2965	Idiopathic pulmonary fibrosis	Study in healthy participants and IPF patients terminated due to development challenges associated with COVID-19 and emerging nonclinical data	8/4/20
Infinity Pharmaceuticls Inc., of Cambridge, Mass.	IPI-549	Cancer	Working with clinical trial investigators and sites to continue patient treatment, but new enrollment is being assessed for each individual patients and the company expects some delays due to COVID-19; several studies are underway for the oral immuno-oncology candidate that selectively inhibits P13K-gamma	4/7/20
Inflarx NV, of Jena, Germany	IFX-1	Various inflammatory indications	While current clinical trial sites remain active, it is possible that sites have paused or will pause screening of new patients, and there may be other delays or consequences as the pandemic evolves	3/31/20
Intra-Cellular Therapies Inc., of New York	ITI-007 (lumateperone tosylate)	Schizophrenia	Suspended due to COVID-19	4/20/20
Inventiva SAS, of Daix, France	Lanifibranor	Nonalcoholic fatty liver disease	Recruitment and screening of new patients in the phase II trial of lanifibranor, which targets PPAR, suspended due to COVID-19; patients already included to continue receiving treatment as per protocol	4/7/20
Ipsen SA, of Paris	Botulinum toxin type A	Vulvodynia	Phase II study temporarily suspended due to COVID-19 at least until 25 April 2020	3/31/20
Ipsen SA, of Paris, and Bristol Myers Squibb Co., of New York	Nal-irinotecan and nivolumab	Advanced biliary tract cancer	Enrollment in phase Ib/II trial testing combination in second-line therapy temporarily paused due to COVID-19	5/1/20
Ironwood Pharmaceuticals Inc., of Boston	IW-3718	Refractory gastroesophageal reflux disease	COVID-19 is impacting enrollment of new patients in the phase III trial due primarily to certain sites suspending enrollment and lower patient participation; nearly 70% have been enrolled to date; top-line data is no longer expected for the second half of 2020	3/26/20
Ironwood Pharmaceuticals Inc., of Boston	IW-3718	Refractory gastroesophageal reflux disease	COVID-19 pandemic impacting enrollment in 2 trials, with most clinical sites no longer screening new patients; top-line data no longer expected in second half of 2020	5/6/20
Iveric Bio Inc., of New York	Zimura (avancipatad pegol)	Geographic atrophy secondary to dry age-related macular degeneration	Delaying the initiation of enrollment of patients in the second pivotal clinical trial, ISEE2008, for the novel complement C5 inhibitor; it was on track to begin in March 2020	3/18/20
Janssen Pharmaceutica NV, a unit of New Brunswick, N.J.-based Johnson & Johnson	Apalutamide (ARN-509)	Prostate cancer patients after prostatectomy	Recruitment in trial comparing apalutamide combined with concomitant prostate-bed salvage radiotherapy (SRT) and androgen deprivation therapy (ADT) vs. concomitant prostate-bed SRT and ADT has been temporary suspended since March 20 due to COVID-19 pandemic	4/24/20
Janssen Pharmaceuticals, a unit of New Brunswick, N.J.-based Johnson & Johnson	Guselkumab	Hidradenitis suppurativa	Study withdrawn due to COVID-19	6/5/20
Janssen Pharmaceuticals, a unit of New Brunswick, N.J.-based Johnson & Johnson	JNJ-54175446	Major depressive disorder	Suspended due to COVID-19	5/18/20
Janssen Pharmaceuticals, a unit of New Brunswick, N.J.-based Johnson & Johnson, and Yuhan Corp., of Seoul, Korea	YH-25448	EGFR-positive advanced non-small-cell lung cancer	Recruitment in phase I/II trial temporarily on hold due to COVID-19	4/28/20
Janssen Research & Development LLC, a unit of New Brunswick, N.J.-based Johnson & Johnson	Loperamide	Antidiarrheal	Study testing effects on electrocardiogram intervals in healthy adults put on hold due to COVID-19	6/22/20
Janssen Research & Development LLC, of Raritan, N.J, a unit of Johnson & Johnson	Macitentan and tadalafil	Pulmonary arterial hypertension	Study in healthy adults suspended due to COVID-19	6/2/20
Janssen Research & Development LLC, part of New Brunswick, N.J.-based Johnson & Johnson	JNJ-61393215	Depression	Recruitment of phase II trial temporarily discontinued due to the COVID-19 pandemic	4/3/20
Janssen Research & Development LLC, part of New Brunswick, N.J.-based Johnson & Johnson	JNJ-67953964	Healthy subjects	Recruitment of phase I trial temporarily discontinued due to the COVID-19 pandemic	4/3/20
Juno Therapeutics Inc., of Seattle	Autologous Anti-BCMA-CAR-expressing CD4+/CD8+ T-lymphocytes FCARH143	Multiple myeloma	Phase I study temporarily suspended due to COVID-19	3/31/20
Juno Therapeutics Inc., of Seattle	BCMA-specific CAR-expressing T Lymphocytes	Recurrent plasma cell myeloma	Phase I study temporarily suspended due to COVID-19	3/31/20
Kadmon Holdings Inc., of New York	KD-025	Systemic sclerosis	Enrollment delayed due to COVID-19	5/7/20
Kalvista Pharmaceuticals Inc., of Cambridge, Mass.	KVD-900	Hereditary angioedema	Data from phase II study of the plasma kallikrein inhibitor delayed due to COVID-19; expects data in second half of 2020 if participants are able to resume their activity during the second quarter of 2020	4/7/20
Karyopharm Therapeutics Inc., of Newton, Mass. and Abbvie Inc., of North Chicago	Venetoclax and Selinexor	Diffuse large B-cell lymphoma and acute myeloid leukemia	Recruitment of phase I trial temporarily suspended due to COVID-19	4/14/20
Kezar Life Sciences Inc., of South San Francisco	KZR-616	Lupus nephritis	Clinical development and data release of the immunoproteasome inhibitor expected to be delayed due to COVID-19, but the open-label portion of the Mission study continues to generate data; next data update expected by the end of the second quarter of 2020	4/9/20
Kezar Life Sciences Inc., of South San Francisco	KZR-616	Active autoimmune hemolytic anemia or immune thrombocytopenia	Marina study withdrawn due to COVID-19-related activity slowdown, high screen fail rate and lack of enrollment	8/5/20
Leo Pharma A/S, of Ballerup, Denmark	Delgocitinib cream	Discoid lupus erythematosus	Trial put on hold due to COVID-19	5/4/20
Leo Pharma A/S, of Ballerup, Denmark	LEO-138559	Atopic dermatitis	Trial in healthy subjects put on hold due to COVID-19	4/27/20
Levo Therapeutics Inc., of Chicago	Intranasal carbetocin (LV-101)	Prader-Willi syndrome	Enrollment in Care-PWS trial paused due to COVID-19	4/20/20
Lexicon Pharmaceuticals Inc., of The Woodlands, Texas	Zynquista (sotagliflozin)	Heart failure and chronic kidney disease	Closing out early the two long-term outcomes studies, Scored and Soloist, because a near-term partnership sufficient to fund the studies to completion is now unlikely due to uncertainties related to the COVID-19 pandemic	3/19/20
Magenta Therapeutics Inc., of Cambridge, Mass.	MGTA-145	Bone marrow transplantation	Initiation of multiple phase II trials of the CXCR2 chemokine agonist may be staggered over remainder of 2020 due to COVID-19 pandemic but initial phase II data may be available by year-end 2020, as planned	4/16/20
Magenta Therapeutics Inc., of Cambridge, Mass.	MGTA-456 (spanlecortemlocel)	Hematopoietic stem cell transplantation	Enrollment timelines for the phase II trial of the AHR gene inhibitor in inherited metabolic disorders shifted into 2021 due to COVID 19 pandemic; 16 of 18 participants enrolled in separate blood cancer trial, expected to complete enrollment in 2020	4/16/20
Mallinckrodt plc, of Staines-upon-Thames, U.K.	Acthar	Keratitis	Phase IV study temporarily suspended due to COVID-19	4/2/20
Mallinckrodt plc, of Staines-upon-Thames, U.K.	Acthar Gel	Uveitis	Phase IV study temporarily suspended due to COVID-19	4/1/20
Mallinckrodt plc, of Staines-upon-Thames, U.K.	Acthar Gel (repository corticotropin injection)	Severe keratitis	Study testing impact on everyday life of patients temporarily suspended due to COVID-19	4/30/20
Marker Therapeutics Inc., of Houston	MultiTAA-specific T-cell therapy	Acute myeloid leukemia	Due to COVID-19, initiation of trial expected to be delayed; Marker paused opening enrollment of first 3 patients, as the manufacturing facility it utilizes to supply study drug remains closed during the pandemic	5/11/20
Matinas Biopharma Holdings Inc., of Bedminster, N.J.	Amphotericin	Cryptococcal meningtitis	Enrollment of new patients in Enact (encochleated oral amphotericin for crytococcal meningitis) has been paused; two patients enrolled and dosed were moved to standard of care	3/31/20
Matinas Biopharma Holdings Inc., of Bedminster, N.J.	MAT-9001	Hypertriglyceridemia	Paused enrollment in the Enhance-IT trial, a head-to-head with Vascepa, due to COVID-19; trial just started March 5	3/31/20
Medexus Pharmaceuticals Inc., of Chicago, Toronto and Montreal	Ixinity	Hemophilia B	COVID-19 is resulting in meaningful delays for its pediatric trial of the intravenous recombinant factor IX therapeutic	3/23/20
Medical Developments International Ltd., of Scoresby, Australia	Penthrox	Acute pain	Phase II study suspended due to substantial study updates and COVID-19	3/25/20
Mediwound Ltd., of Yavne, Israel	Escharex	Venous leg ulcers	Enrollment suspended in phase II trial of the topical enzyme proteolytic therapy due to COVID-19 outbreak	3/30/20
Mediwound Ltd., of Yavne, Israel	Escharex (bromelain gel)	Venous leg ulcers	Size of adaptive design study reduced to enrollment target of 120 participants from 174 due to COVID-19-related enrollment delays and potential disruptions; interim assessment expected in mid-2021 with full enrollment expected by year-end 2021	1/11/21
Merck & Co. Inc., of Kenilworth, N.J.	Aldesleukin and Pembrolizumab	Advanced or metastatic kidney cancer	Phase I study temporarily suspended due to COVID-19	3/31/20
Merck KGaA, of Darmstadt, Germany	M-5717	Healthy subjects	Phase I study temporarily suspended due to COVID-19	3/30/20
Merck, Sharp & Dohme Corp., part of Kenilworth, N.J.-based Merck & Co. Inc.	MK-8228 (letermovir)	Prevention of human cytomegalovirus infection and disease	Trial testing drug in adult Japanese kidney transplant recipients suspended due to COVID-19	5/6/20
Merck, Sharp & Dohme Corp., part of Merck & Co. Inc., of Kenilworth, N. J.	Bezlotoxumab	Clostridium difficile infection	Study testing secondary prophylaxis in high-risk hospitalized patients exposed to antibiotics temporarily paused due to COVID-19	5/15/20
Mesoblast Ltd., of Melbourne, Australia	Remestemcel-L	COVID-19	Started enrolling in phase II/III placebo-controlled study to measure whether remestemcel-L provides survival benefit in moderate/severe acute respiratory distress syndrome due to COVID-19	4/30/20
Millendo Therapeutics Inc., of Ann Arbor, Mich.	Nevanimibe	Classic congenital adrenal hyperplasia	Due to COVID-19, new patients are not being actively enrolled in phase IIb study at this time; company expects to conduct interim review of current dataset for enrolled patients by the third quarter of 2020	5/8/20
Moderna Inc., of Cambridge, Mass.	mRNA-1653	Human metapneumovirus and parainfluenza type 3	Pausing new enrollment of its age de-escalation trial for its pediatric respiratory vaccine due to COVID-19	3/30/20
Moderna Inc., of Cambridge, Mass.	mRNA-3704	Methylmalonic acidemia	Pausing new enrollment of its phase I rare disease trials due to disruption from COVID-19	3/30/20
Moderna Inc., of Cambridge, Mass.	mRNA-3927	Propionic acidemia	Pausing new enrollment of its phase I rare disease trials due to disruption from COVID-19	3/30/20
Momenta Pharmaceuticals Inc., of Cambridge, Mass.	M-281	Warm autoimmune hemolytic anemia	Recruitment paused due to COVID-19 pandemic	4/15/20
Momenta Pharmaceuticals Inc., of Cambridge, Mass.	M-281	Generalized myasthenia gravis	Recruitment paused due to COVID-19 pandemic	4/15/20
Momenta Pharmaceuticals Inc., of Cambridge, Mass.	M-254 (hypersialylated immunoglobulin)	Idiopathic thrombocytopenic purpura	Most sites suspended enrollment in ongoing phase I/II trial due to COVID-19 pandemic; interim data for part B may not report as planned in second quarter of 2020, which would delay initiation of parts C and D; Dendritic ICAM-3 grabbing nonintegrin 1 modulator	4/2/20
Momenta Pharmaceuticals Inc., of Cambridge, Mass.	M-254 (hypersialylated immunoglobulin)	Chronic inflammatory demyelinating polyneuropathy	Trial now expected to begin in 2021 due to COVID-19-related delays; Dendritic ICAM-3 grabbing nonintegrin 1 modulator	4/2/20
Momenta Pharmaceuticals Inc., of Cambridge, Mass.	Nipocalimab (M-281)	Hemolytic disease of fetus and newborn; warm autoimmune hemolytic anemia	Although not officially paused, Unity study in HDFN expected to enroll at slower pace due to impact of COVID-19 pandemic; global site activation continues in adaptive phase II/III Energy study in wAIHA but enrollment temporarily suspended; IgG receptor FcRn large subunit p51 antagonist	4/2/20
Morphosys AG, of Martinsried, Germany	MOR-202	Anti-PLA2R+ membranous nephropathy	Recruitment paused in phase I/II study due to COVID-19	4/28/20
Myokardia Inc., of Brisbane, Calif.	Danicamtiv	Genetic dilated cardiomyopathy	COVID-19 is delaying the start of the phase II study	3/26/20
Myokardia Inc., of Brisbane, Calif.	Mavacamten	Heart conditions	COVID-19 is delaying the start of the Valor-HCM phase III study for its use as an alternative to septal reduction therapy procedures and the phase II study in subgroups of patients with heart failure with preserved ejection fraction	3/26/20
Neoimmunetech Inc., of Cambridge, Mass.	rhIL-7-hyFc	Glioma	Suspended trial in patients with newly diagnosed non-lymphopenic gliomas following radiation and temozolomide due to COVID-19	4/22/20
Neurocrine Biosciences Inc., of San Diego	Crinecerfont	Congenital adrenal hyperplasia	Phase II enrollment paused due to COVID-19	4/3/20
Neurocrine Biosciences Inc., of San Diego	Ingrezza (valbenazine )	Chorea in Huntington disease	Phase III enrollment paused due to COVID-19	4/3/20
Neurocrine Biosciences Inc., of San Diego, and Voyager Therapeutics Inc., of Cambridge, Mass.	NBIb-1817	Parkinson's disease	Phase II enrollment in the Restore-1 study paused due to COVID-19	4/3/20
Newron Pharmaceuticals SpA, of Milan, Italy	Evenamide	Schizophrenia	Expects a delay in the start of its planned studies, due to the prioritiation of hospital staff to care for COVID-19 patients over research studies	3/31/20
Nextcure Inc., of Beltsville, Md.	NC-318	Advanced solid tumors	Company continuing to support those enrolled in phase II portion of phase I/II monotherapy trial of the sialic acid-binding lg-like lectin 15 inhibitor and working with sites to enroll additional participants as appropriate in light of COVID-19 pandemic; initial biomarker data from phase I portion expected in midyear 2020 but top-line data from phase II portion expected to be delayed	4/13/20
Nextcure Inc., of Beltsville, Md.	NC-318	Advanced solid tumors; non-small-cell lung cancer	Initiation of combination trial of the sialic acid-binding Ig-like lectin 15 inhibitor with standard-of-care chemotherapies delayed due to COVID-19 pandemic	4/13/20
Nextcure Inc., of Beltsville, Md.	NC-410	Undisclosed cancer	Initiation of phase I portion of phase I/II trial of the leukocyte associated Ig like receptor 1 antagonist, originally expected to begin in March, delayed due to COVID-19 pandemic	4/13/20
Northwest Biotherapeutics Inc., of Bethesda, Md.	Dcvax-L	Glioblastoma	COVID-19 has delayed final data collection; expected to be complete in mid-June 2020 or shortly thereafter	6/2/20
Novartis AG, of Basel, Switzerland	CFZ-533	Type 1 diabetes	Treatment and recruitment paused due to COVID-19	4/15/20
Novartis AG, of Basel, Switzerland	BAF-312 (siponimod)	Intracerebral hemorrhage	Recruitment temporarily paused due to COVID-19	5/4/20
Novartis AG, of Basel, Switzerland	Brolucizumab	Macular edema secondary to retinal vein occlusion	Trial temporarily paused due to COVID-19 and safety measure	6/1/20
Novartis AG, of Basel, Switzerland	Brolucizumab	Diabetic macular edema	Study testing drug vs. aflibercept in patients with visual impairment due to DME canceled due to COVID-19	3/4/21
Novartis AG, of Basel, Switzerland	Canakinumab	Early stage non-small-cell lung cancer	Recruitment temporarily paused due to COVID-19 in study testing canakinumab or Keytruda (pembrolizumab, Merck & Co. Inc.) as monotherapy or combination therapy in neoadjuvant treatment	4/28/20
Novartis AG, of Basel, Switzerland	CFZ-533	Sjogren’s syndrome	Recruitment of phase II trial temporarily suspended due to the COVID-19 pandemic	4/13/20
Novartis AG, of Basel, Switzerland	Crizanlizumab	Sickle cell disease	Recruitment temporarily paused due to COVID-19 in trial enrolling adolescent and adult patients	4/28/20
Novartis AG, of Basel, Switzerland	Crizanlizumab	Sickle cell disease	Recruitment in study enrolling pediatric patients temporarily paused due to COVID-19	5/1/20
Novartis AG, of Basel, Switzerland	Entresto (sacubitril/valsartan)	Heart failure with preserved ejection fraction	Recruitment temporarily paused due to COVID-1	4/17/20
Novartis AG, of Basel, Switzerland	Sacubitril/Valsartan	Chronic Chagas' cardiomyopathy	Recruitment of phase IV trial temporarily paused due to the COVID-19 pandemic	4/13/20
Novartis AG, of Basel, Switzerland	Secukinumab	Necrobiosis lipoidica diabeticorum	Enrollment and other trial activities paused due to COVID-19 pandemic	4/24/20
Novartis AG, of Basel, Switzerland	Secukinumab	Plaque psoriasis and coexisting nonalcoholic fatty liver disease	Study suspended due to COVID-19	4/28/20
Novartis AG, of Basel, Switzerland	Secukinumab	Hidradenitis suppurativa	Suspended due to COVID-19	4/28/20
Novartis AG, of Basel, Switzerland	Spartalizumab	Unresectable or metastatic melanoma	Recruitment paused due to COVID-19 pandemic	4/24/20
Novartis AG, of Basel, Switzerland	Tropifexor/licogliflozin	Nonalcoholic steatohepatitis	Recruitment suspended due to COVID-19 pandemic	4/24/20
Novo Nordisk A/S, of Bagsvaerd, Denmark	Degludec	Type 2 diabetes	Recruitment in study comparing drug and glargine U100 for management of hospitalized and discharged patients suspended due to COVID-19	5/4/20
Novo Nordisk A/S, of Bagsvaerd, Denmark	Liraglutide	Type 2 diabetes	Recruitment suspended in hospital discharge trial due to COVID-19	5/4/20
Novocure Ltd., of St. Helier, Jersey	Optune	Newly diagnosed unresectable glioblastoma	Recruitment temporarily suspended due to COVID-19 pandemic	4/24/20
Obi Pharma Inc., of Taipei, Taiwan	Adagloxad simolenin	Triple-negative breast cancer	Pausing the Gloria study of the antibody-drug conjugate targeting Clobo H for 3 months due to COVID-19	4/8/20
Obseva SA, of Geneva	Lizagolix	Endometriosis	Screening and randomization in ongoing Edelweiss 2 and 3 trials is placed on voluntary hold due to COVID-19; Linzagolix is a GNRH receptor antagonist	3/23/20
Ocular Therapeutix Inc., of Bedford, Mass.	Dextenza	Cataract	Recruitment of phase IV trial was temporarily suspended due to the COVID-19 pandemic	4/3/20
Opiant Pharmaceuticals Inc., of Santa Monica, Calif.	OPNT-002 (naltrexone hydrochloride, intranasal)	Alcohol use disorder	Paused initiation of recruitment due to COVID-19 pandemic	5/12/20
Oramed Pharmaceuticals Inc., of New York	Oral leptin edrug candidate	Type 1 diabetes	Delaying its exploratory clinical study due to the COVID-19 outbreak	4/1/20
Orchard Therapeutics plc, of London	OTL-101 (simoladagene autotemcel)	Severe combined immunodeficiency	COVID-19-related clinical and manufacturing impacts expected to delay initiation of rolling BLA to FDA, previously planned for first half of 2020	4/1/20
Orchard Therapeutics plc, of London	OTL-103	Wiskott-Aldrich syndrome	Enrollment timelines in ongoing trial expected to shift by at least 3 months due to COVID-19 pandemic	4/1/20
Orchard Therapeutics plc, of London	OTL-200	Metachromatic leukodystrophy	Despite continuing engagement with EMA on submitted MAA under accelerated assessment, decision likely to be postponed due to COVID-19 pandemic; potential launch in Europe now expected in first half of 2021; BLA submission to FDA also postponed to first half of 2021	4/1/20
Orchard Therapeutics plc, of London	OTL-201	Mucopolysaccharidosis type IIIA (Sanfilippo syndrome)	Enrollment timelines in ongoing phase I/II program expected to shift by at least 3 months due to COVID-19 pandemic	4/1/20
Orphomed Inc., of San Francisco	ORP-101	Irritable bowel syndrome with diarrhea	Paused new patient recruitment for its phase II trial in response to the COVID-19 pandemic	3/31/20
Oryzon Genomics SA, of Madrid, Spain	Vafidemstat (ORY-2001)	Agitation-aggression in borderline personality disorder	Decided to postpone activation of phase IIb trial for a few months due to COVID-19 lockdown	4/17/20
OSE Immunotherapeutics, of Nantes, France	Tedopi	Pancreatic cancer	Patient screening and accrual in the Tedopam study are expected to be impacted by the COVID-19 situation in the coming months	3/26/20
OSE Immunotherapeutics, of Nantes, France	Tedopi	Non-small-cell lung cancer	Hit the primary endpoint in the first part of a phase III trial, but had to terminate without completing the crucial second part, due to the vulnerability of patients with metastatic NSCLC during the COVID-19 pandemic	4/1/20
OSE Immunotherapeutics, of Nantes, France, and Boehringer Ingelheim	BI-765063 (formerly OSE-172)	Solid tumors	Phase I trial is expected to be impacted by COVID-19 with regard to the screening and accrual of new patients in the second quarter of 2020	3/26/20
OSE Immunotherapeutics, of Nantes, France, and Servier	OSE-127	Sjögren’s syndrome	Initiation of both phase II trials in 2020 is subject to the evolution of the COVID-19 situation	3/26/20
Otonomy Inc., of San Diego	OTO-413	Speech-in-noise-hearing difficulty	Study, which has completed several dose cohorts of the brain-derived neurotrophic factor, is paused due to COVID-19	4/9/20
Outlook Therapeutics Inc., of Cranbury, N.J.	ONS-5010/Lytenava (bevacizumab-vikg)	Wet age-related macular degeneration	Final enrollment in Norse 2 phase III registration trial of the VEGF ligand inhibitor expected to be delayed by 1 to 3 months due to COVID-19 pandemic	4/14/20
Oxurion NV, of Leuven, Belgium	THR-687	Diabetic macular edema	Delayed start of planned study to test multiple doses of drug due to COVID-19 pandemic; trial to start as soon as conditions allow	5/7/20
Oyster Point Pharma Inc., of Princeton, N.J.	OC-01	Dry eye disease	Completed enrollment of 758 patients in the Onset-2 phase III study; data expected by the end of the second quarter of 2020; day 28 data impacted by COVID-19, which is predicted to reduce power for primary endpoint to 99%	3/30/20
Palatin Technologies Inc., of Cranbury, N.J.	PL-8177	Ulcerative colitis	Delay of 2 quarters due to COVID-19; study now targeted to start in first half of 2021, with data readout in first half of 2022	4/30/20
Palatin Technologies Inc., of Cranbury, N.J.	PL-9643	Dry eye disease	Enrollment of additional cohorts delayed due to COVID-19; anticipates restarting enrollment in June 2020, and data readout remains on track for fourth quarter of 2020	4/30/20
Paratek Pharmaceuticals Inc., of Boston	Various drugs	Various indications	Pausing its ongoing clinical studies due to COVID-19	4/2/20
PCI Biotech AS, of Oslo, Norway	Fimachem	Bile duct cancer	COVID-19 has affected the opening of new trial sites and new patient enrollment in the Release study	3/25/20
PDS Biotechnology Corp., of Princeton, N.J.	PDS-0101	Head and neck cancer	Initiation of Versatile-0022 phase II trial of the cationic lipid nanoparticle formulated vaccine in individuals with advanced/metastatic disease delayed due to COVID-19 pandemic	4/16/20
Pfizer Inc., of New York	Glasdegib	Acute myeloid leukemia	Temporary recruitment hold for trial in older patients with poor-risk AML due to COVID-19	7/2/20
Pfizer Inc., of New York	Various drugs	Various indications	Due to COVID-19, pausing for three weeks the recruitment portion of new and ongoing clinical studies, including those for oncology and for its Duchenne muscular dystrophy gene therapy program	3/26/20
Pharming Technologies B.V. of Leiden, the Netherlands	Ruconest	Kidney failure	Phase I study temporarily suspended due to COVID-19	3/27/20
Phasebio Pharmaceuticals Inc., of Malvern, Pa.	PB-1046	Pulmonary arterial hypertension	Pausing enrollment in the phase II study of the sustained-release vasoactive intestinal peptide analogue due to COVID-19	3/30/20
Phathom Pharmaceuticals Inc., of Florham Park, N.J.	Vonoprazan	Erosive esophagitis and H. pylori infection	Pausing new patient randomization in its Phalcon-EE and Phalcon-HP clinical trials due to global efforts to combat COVID-19	3/19/20
Precigen Inc., of Germantown, Md.	PRGN-3005	Advanced recurrent platinum resistant ovarian, fallopian tube or primary peritoneal cancer	Phase I study suspended due to COVID-19	3/30/20
Prilenia Therapeutics BV, of Naarden, the Netherlands	Pridopidine	Levodopa-induced dyskinesia in Parkinson’s disease	Study terminated due to COVID-19	11/9/20
Progenics Pharmaceuticals Inc., of New York	1095	Metastatic castration-resistant prostate cancer	Due to COVID-19, decided to place enrollment of new patients on hold in Arrow study testing combination with enzalutamide in chemotherapy-naïve patients	5/7/20
Prometic Biosciences Inc., of Laval, Quebec	PBI-4050	Alstrom syndrome	Phase II/III study terminated early due to redeployment of study site staff during COVID-19 pandemic	10/30/20
Proqr Therapeutics NV, of Leiden, the Netherlands, and Cambridge, Mass.	QR-1123	Retinitis pigmentosa	Enrollment paused due to COVID-19 pandemic	3/31/20
Proqr Therapeutics NV, of Leiden, the Netherlands, and Cambridge, Mass.	QR-421a	Usher syndrome	Enrollment paused in the phase I/II trial due to COVID-19 pandemic	3/31/20
Proqr Therapeutics NV, of Leiden, the Netherlands, and Cambridge, Mass.	QR-504a	Corneal dystrophy	Trial start delayed due to COVID-19 pandemic	3/31/20
Proqr Therapeutics NV, of Leiden, the Netherlands, and Cambridge, Mass.	Sepofarsen	Leber congenital amaurosis 10	Delays are expected in all ongoing and scheduled trials, including the pivotal trial of sepofarsen, due to COVID-19	3/31/20
Provention Bio Inc., of Oldwick, N.J.	PRV-031 (teplizumab)	Type 1 diabetes	Pausing the randomization of patients into its global phase III Protech study; those undergoing study therapy will be allowed to complete their course, as recommended by the study's Data Safety Monitoring Board, which was expanded to include infectious diseases expertise; company remains on track to complete a rolling BLA to the FDA in the fourth quarter of 2020	3/16/20
Pulmatrix Inc., of Lexington, Mass.	PUR-1900	Allergic bronchopulmonary Aspergillosis	Study suspended due to COVID-19 pandemic	6/9/20
Pulmocide Ltd., of London	PC-945	Aspergillus fumigatus lung infection in lung transplant	Study terminated early due to COVID-19	6/12/20
Pulmocide Ltd., of London	PC-945	Aspergillus fumigatus lung infection in cystic fibrosis	Study terminated early due to COVID-19	6/12/20
Pulmocide Ltd., of London	PC-945	Aspergillus or Candida lung infections in asthma or chronic respiratory disease	Study terminated early due to COVID-19	6/12/20
Quantum Genomics SAS, of Paris	QGC-001	End-stage renal failure	All patients with renal failure enrolled and treated in the phase I trial of the aminopeptidase A inhibitor; half of healthy volunteers completed the trial but enrollment temporarily halted due to COVID-19; in order to limit impact to trial, company will conduct interim analysis	4/7/20
Reata Pharmaceuticals Inc., of Plano, Texas	Bardoxolone methyl	Connective tissue disease-associated pulmonary arterial hypertension	Due to the risk of severe, adverse outcomes associated with COVID-19 among patients with respiratory and autoimmune diseases, company has stopped the phase III Catalyst study; company is also closing Ranger, the open-label extension study	3/31/20
Reata Pharmaceuticals Inc., of Plano, Texas	Bardoxolone methyl	Autosomal dominant polycystic kidney disease	Paused enrollment of new patients in the phase III Falcon trial, due to COVID-19	3/31/20
Redhill Biopharma Ltd., of Tel Aviv, Israel	RHB-204	Pulmonary nontuberculous mycobacteria infections	Initiation of the pivotal phase III trial is delayed by one quarter to the third quarter of this year due to the COVID-19 virus outbreak	3/25/20
Regenerx Biopharmaceuticals Inc., of Rockville, Md.	RGN-259	Dry eye syndrome	Completion of the Arise-3 study expected to be delayed by approximately 2 months due to COVID-19	6/2/20
Reneuron Group plc, of London	ReN-001	Stroke disability	COVID-19 pandemic is affecting most studies, including in the U.S., where it is running trials with its stem cell therapy candidates; company expects delays in additional recruitment	4/7/20
Reneuron Group plc, of London	ReN-003	Retinitis pigmentosa	COVID-19 pandemic is affecting most studies, including in the U.S., where it is running trials with its stem cell therapy candidates; company expects delays in additional recruitment	4/7/20
Respivant Sciences Inc., of San Diego	RVT-1601	Persistent cough in idiopathic pulmonary fibrosis	Terminated due to COVID-19	6/11/20
Restorbio Inc., of Boston	RTB-101	Parkinson’s disease	Postponing enrollment of fifth cohort in the phase I due to COVID-19	4/3/20
Retinset SL, of Barcelona, Spain	Bosentan	Type 2 diabetes	Suspended due to COVID-19 restrictions in Spain	5/22/20
Revance Therapeutics Inc., of Newark, Calif.	DaxibotulinumtoxinA (DAXI)	Adult upper limb spasticity	Paused its phase II Juniper trial due to limitations placed upon the study by COVID-19	3/27/20
Revance Therapeutics Inc., of Newark, Calif.	RT-002	Upper limb spasticity	Disclosed pause in enrollment in Juniper trial in adults due to COVID-19	5/7/20
Rezolute Inc., of Redwood City, Calif.	RZ-358	Congenital hyperinsulinism	Enrollment in recently initiated phase IIb study paused due to COVID-19; company no longer expects to report mid-study data by fourth quarter 2020	5/15/20
Rheacell GmbH & Co. KG, of Heidelberg, Germany	Allo-APZ2-PAOD	Peripheral arterial occlusive disease	Phase I/II study terminated due to very slow enrollment amid COVID-19 pandemic	6/29/20
Rhovac AB, of Stockholm	RV-001	Prostate cancer	Phase IIb Bravac study delayed as COVID-19 vaccinations are rolled out to study population	3/8/21
Rhovac AB, of Stockholm	RV-001	Prostate cancer	Recruitment being delayed due to COVID-19; company expects existing financing will cover the expected delay; Antigen-based cancer therapy	4/2/20
Roche Holding AG, of Basel, Switzerland	Atezolizumab	Muscle invasive bladder cancer	Study in patients with MIBC not eligible for radical cystectomy suspended due to COVID-19	4/22/20
Roche Holding AG, of Basel, Switzerland	Entrectinib	Cancer	Due to COVID-19, recruitment on hold to assess effect of impaired hepatic function on pharmacokinetics in volunteers with different levels of hepatic function	5/14/20
Roche Holding AG, of Basel, Switzerland	Port Delivery System with Ranibizumab	Diabetic macular edema	Recruitment of phase III trial temporarily suspended due to the COVID-19 pandemic	4/7/20
Roche Holding AG, of Basel, Switzerland	Ranibizumab	Diabetic macular edema	Enrollment in study comparing port delivery system to intravitreal administration temporarily paused due to COVID-19	5/19/20
Sanofi Pasteur, a unit of Sanofi SA, of Paris	VRVg-2	Rabies	Suspended due to COVID-19	4/30/20
Sanofi SA, of Paris	Jevtana (cabazitaxel)	High-risk localized prostate cancer	Trial testing cabazitaxel and pelvic radiotherapy has been temporary suspended since March 20 due to COVID-19 pandemic	4/24/20
Sanofi SA, of Paris	Quadrivalent meningococcal conjugate vaccine	Healthy subjects	Recruitment of phase III trial was suspended due to the COVID-19 pandemic	4/3/20
Sanofi SA, of Paris	Quadrivalent meningococcal conjugate vaccine	Meningococcal Infections	Recruitment of phase III trial was suspended due to the COVID-19 pandemic	4/3/20
Sanofi SA, of Paris	VYF-01	Yellow fever virus infection	Phase I/II study suspended due to COVID-19	4/15/20
Sanofi SA, of Paris, and Regeneron Pharmaceuticals Inc., of Tarrytown, N.Y.	Kevzara (sarilumab)	Polymyalgia rheumatica	Recruitment temporarily halted as a precautionary measure due to the COVID-19 pandemic	4/17/20
Sanofi SA, of Paris, and Regeneron Pharmaceuticals Inc., of Tarrytown, N.Y.	Kevzara (sarilumab)	Giant cell arteritis	Study suspended due to COVID-19	4/17/20
Savara Inc., of Austin, Texas	Molgradex	Nontuberculous mycobacterial lung infection	Due to COVID-19 concerns, company closed enrolled in phase IIa Encore study	5/8/20
Savara Inc., of Austin, Texas	Molgradex	Nontuberculous mycobacterial lung infection in patients with cystic fibrosis	Stopping Encore study due to impact of COVID-19 on recruitment and continued participation as well as the impact of the approval of Trikafta (elexacaftor/tezacaftor/ivacaftor and ivacaftor, Vertex Pharmaceuticals Inc.)	9/3/20
Scholar Rock Inc., of Cambridge, Mass.	SRK-015	Spinal muscular atrophy	COVID-19-related restrictions have impacted patient access sites in Topaz trial, which have led to missed or delayed doses or assessments in some patients and affected ability to monitor trial data collected by sites; interim data now expected in fourth quarter of 2020, roughly a 1-month delay to previous guidance	5/7/20
Sensorion, of Montpelier, France	SENS-401 (arazasetron)	Sudden sensorineural hearing loss	Due to the reprioritization of emergency room resources due to COVID-19, the phase II Audible-S trial is recruiting patients at a slower pace than expected; company has revised its estimate for top-line data readout to mid-year 2021	3/13/20
Seres Therapeutics Inc., of Cambridge, Mass.	SER-109	Clostridium difficile infection	Completed enrollment of Ecospor III trial at 181 individuals with recurrent disease; enrollment halted prior to expected 188 participants due to COVID-19 pandemic; top-line results expected in mid-2020	3/30/20
Seres Therapeutics Inc., of Cambridge, Mass.	SER-287	Ulcerative colitis	Phase IIb study about 60% enrolled based on 201-patient target size but development adversely affected by clinical sites halting non-essential procedures, including endoscopies, due to COVID-19; trial may not achieve original enrollment target in second half of 2020	3/30/20
Seres Therapeutics Inc., of Cambridge, Mass.	SER-401	Metastatic melanoma	Enrollment voluntarily discontinued due to impact of COVID-19 pandemic; 10 participants currently enrolled will complete study protocol but additional development deprioritized	3/8/21
Silence Therapeutics plc, of London	SLN-124	Beta-thalassemia or myelodysplastic syndromes	Study stopped prior to first administered dose due to COVID-19	4/27/20
Sojournix Inc., of Waltham, Mass.	SJX-653	Vasomotor symptoms	Enrollment of postmenopausal women halted due to COVID-19	4/21/20
Spark Therapeutics Inc., of Philadelphia, a member of the Roche Group	SPK-3006	Late-onset Pompe disease	Phase I/II study suspended until further notice due to COVID-19	5/18/20
Sun Biopharma Inc., of Minneapolis	SBP-101	Pancreatic cancer	Enrollment paused in the phase I trial of the caspase-3 stimulator due to COVID-19 pandemic in ongoing dose-escalation and expansion combination study with nab-paclitaxel and gemcitabine; currently enrolled participants will remain on treatment	4/6/20
Synairgen plc, of Southampton, U.K.	SNG-001 (inhaled formulation of interferon-beta-1a)	Chronic obstructive pulmonary disease	With 109 out of a target 120 participants already dosed in a phase II study, the trial has been paused to minimize infection risk and the distraction of respiratory staff needed for patients with COVID-19; company received approval from the Medicines and Healthcare products Regulatory Agency and Health Research Authority to conduct a trial of SNG-001 in COVID-19	3/18/20
Syncona Ltd., of London	Various drugs	Various indications	The life sciences investor said its firms have made or are considering appropriate plans for delays of up to three months to clinical trials due to COVID-19	3/23/20
Synlogic Inc., of Cambridge, Mass.	SYNB-1618	Phenylketonuria	Trial enrollment delayed due to COVID-19 outbreak	3/30/20
T3D Therapeutics Inc., of Research Triangle Park, N.C.	T3D-959	Alzheimer’s disease	Study suspended due to COVID-19	6/23/20
Taiho Oncology Inc., of Princeton, N.J.	TAS-102 in combination with temozolomide	Metastatic pancreatic neuroendocrine tumors	Phase I study suspended due to COVID-19	3/25/20
TC Biopharm Ltd, of Glasgow, U.K.	TCB-002	Acute myeloid leukemia	Recruitment suspended due to COVID-19 pandemic	4/24/20
Tersera Therapeutics LLC, of Lake Forest, Ill.	Rolapitant	Malignant glioma	Trial testing drug as antiemetic following radiotherapy and temozolomide suspended due to COVID-19	4/22/20
Tetra Bio-Pharma Inc., of Ottawa	Caumz	Cancer pain	Serenity and Reborn activities are being slowed by COVID-19; the phase III Serenity study is testing the cannabinoid drug in advanced cancer pain, while Reborn is a phase II program testing Caumz vs. fentanyl in breakthrough pain in cancer patients	3/23/20
Theralase Technologies Inc., of Toronto	TLD-1433	Non-muscle invasive bladder cancer	Enrollment of new patients and conducting the first treatment procedure in the Phase II study has been temporarily placed on holding due to the COVID-19 pandemic	3/20/20
Theravance Biopharma Inc., of Dublin	Ampreloxetine (TD-9855)	Symptomatic neurogenic orthostatic hypertension	Data from 4-week Sequoia trial originally planned for late 2020 is now expected in 2021; delay due to 4-week suspension of new enrollment in response to COVID-19	5/6/20
Theravance Biopharma Inc., of Dublin	TD-1473	Ulcerative colitis	Data from phase IIb portion of phase IIb/III Rhea maintenance study originally planned for late 2020 is now expected in 2021; delay due to 4-week suspension of new enrollment in response to COVID-19	5/6/20
Theravance Biopharma Inc., of Dublin	TD-1473	Crohn’s disease	Data from Dione study originally planned in late 2020 is now expected in 2021; delay due to 4-week suspension of new enrollment in response to COVID-19	5/6/20
Translate Bio Inc., of Lexington, Mass.	MRT-5005	Cystic fibrosis	Company anticipates related interruptions in enrollment, dosing and follow-up due to COVID-19; MRT-5005 is an inhaled mRNA therapeutic	3/27/20
Trillium Therapeutics Inc., of Cambridge, Mass.	TTI-621	Hematologic cancers and solid tumors	First participant in 1.4-mg/kg cohort dosed and on therapy; slowdown or pause in enrollment expected due to COVID-19 pandemic; TTI-621 is a CD47 antagonist	4/8/20
Trillium Therapeutics Inc., of Cambridge, Mass.	TTI-622	Hematologic cancer	First participant in 8-mg/kg cohort dosed and on therapy; slowdown or pause in enrollment expected due to COVID-19 pandemic; TTI-622 is a CD47 antagonist	4/8/20
UCB Biopharma SPRL, of Brussels, Belgium	Cimzia (certolizumab pegol)	Moderate to severe chronic plaque psoriasis	Recruitment temporarily halted as a precautionary measure due to the COVID-19 pandemic	4/17/20
UCB Biopharma SPRL, of Brussels, Belgium	UCB-0107	Progressive supranuclear palsy	Recruitment of phase I trial temporarily halted due to COVID-19	4/13/20
UCB SA, of Brussels	Brivaracetam	Electroencephalographic neonatal seizures	Recruitment temporarily halted due to COVID-19 pandemic	4/17/20
UCB SA, of Brussels	Bimekizumab	Active psoriatic arthritis	Suspended enrollment in Be Optimal trial due to COVID-19	4/20/20
UCB SA, of Brussels	Bimekizumab	Active ankylosing spondylitis	Recruitment in Be Mobile 2 trial suspended due to COVID-19	4/20/20
UCB SA, of Brussels	Bimekizumab	Active nonradiographic axial spondyloarthritis	Recruitment in Be Mobile 1 trial suspended due to COVID-19	4/22/20
UCB SA, of Brussels	Bimekizumab	Autoinflammatory disease	Suspended enrollment of healthy participants due to COVID-19	4/21/20
UCB SA, of Brussels	Brivaracetam	Epilepsy	Enrollment in study testing drug in patients, ages 1 month to < 16 years halted due to COVID-19	4/20/20
UCB SA, of Brussels	Padsevonil	Epilepsy	Suspended study testing interaction with ethanol or cannabidiol due to COVID-19	4/20/20
UCB SA, of Brussels	Padsevonil	Epilepsy	Suspended trial testing drug in patients with normal or moderately impaired hepatic function due to COVID-19	4/21/20
UCB SA, of Brussels	Rozanolixizumab	Chronic inflammatory demyelinating polyradiculoneuropathy	Suspended MyCIDPchoice study due to COVID-19	4/20/20
UCB SA, of Brussels	Rozanolixizumab	Generalized myasthenia gravis	Recruitment suspended due to COVID-19	4/20/20
UCB SA, of Brussels	Rozanolixizumab	Persistent or chronic primary immune thrombocytopenia	Recruitment in MyopportunITy1 trial suspended due to COVID-19	4/20/20
UCB SA, of Brussels	UCB-7858	Kidney transplant	Halted enrollment of patients with chronic allograft injury due to COVID-19	4/20/20
UCB SA, of Brussels, Belgium	Bimekizumab	Active psoriatic arthritis	Study recruitment has been temporarily halted as a precautionary measure due to the COVID-19 pandemic	4/24/20
Uniqure NV, of Lexington, Mass., and Amsterdam)	AMT-130	Huntington's disease	Postponing procedures of the first two enrolled patients in the Phase I/II trial due to the impact of COVID-19	3/26/20
United Therapeutics Corp., of Silver Spring, Md.	Orenipro (treprostinil diolamine prodrug)	Pulmonary artery hypertension	Enrollment paused due to COVID-19 epidemic	4/29/20
United Therapeutics Corp., of Silver Spring, Md.	Ralinepag	Pulmonary artery hypertension	Due to COVID-19 pandemic, enrollment paused in Advance Outcomes and Advance Capacity studies	4/29/20
United Therapeutics Corp., of Silver Spring, Md.	Treprostinil (inhaled)	Pulmonary hypertension	Due to COVID-19 pandemic, enrollment paused in Sapphire study in individuals with pulmonary hypertension due to sarcoidosis	4/29/20
United Therapeutics Corp., of Silver Spring, Md.	Treprostinil Technosphere (inhaled)	Pulmonary artery hypertension	Enrollment paused in phase Ib Breeze and pivotal pharmacokinetics studies due to COVID-19 epidemic	4/29/20
United Therapeutics Corp., of Silver Spring, Md.	Tyvaso (inhaled sustained-release treprostinil)	Pulmonary hypertension	Due to COVID-19 pandemic, enrollment paused in Perfect open-label extension study in individuals with pulmonary hypertension due to chronic obstructive pulmonary disease	4/29/20
US Worldmeds LLC, of Louisville, Ky.	Lucemyra	Opioid withdrawal	Recruitment of phase II trial temporarily suspended due to the COVID-19 pandemic	4/10/20
Vaccinex Inc., of Rochester, N.Y.	Pepinemab	Huntington’s disease	Despite delayed assessments on 2 participants due to COVID-19 pandemic, potentially pivotal Signal trial expected to complete as expected, with database lock by September 2020 and top-line data potentially by early October 2020; following FDA input, efficacy results for 265 enrolled participants will be analyzed in 2 groups: co-primary endpoints for first group (n=179) diagnosed with early manifest disease are Clinical Global Impression of Change from baseline through 18 months of treatment and selected cognitive assessments from Huntington’s Disease Cognitive Assessment Battery; single primary endpoint for second group of all participants, representing continuum of disease, is Total Functional Capacity	7/7/20
Valneva SE, of Saint, Herblain, France	VLA-1533	Chikungunya	Company is preparing for phase III initiation as soon as the COVID-19 situation permits and potentially in the fourth quarter of 2020	3/25/20
Veloxis Pharmaceuticals A/S, of Copenhagen	Envarsus XR (tacrolimus extended-release tablets)	Simultaneous kidney and pancreas transplantation	Recruitment suspended due to COVID-19 pandemic	4/17/20
Venatorx Pharmaceuticals Inc., of Malvern, Pa.	VNRX-5024	Bacterial infection	Trial in healthy adult volunteers suspended due to COVID-19	5/15/20
Venatorx Pharmaceuticals Inc., of Malvern, Pa.	VNRX-5024	Healthy subjects	Recruitment of phase I trial temporarily suspended due to COVID-19	4/9/20
Venatorx Pharmaceuticals Inc., of Malvern, Pa.	VNRX-7145	Healthy subjects	Phase I study enrollement suspended due to COVID-19	3/26/20
Verona Pharma plc, of London	Ensifentrine (pressurized metered-dose inhaler)	Chronic obstructive pulmonary disease	Enrollment in part B of its phase II trial delayed due to COVID-19 pandemic	3/31/20
Vertex Inc., of Boston	VX-814	Alpha-1 antitrypsin deficiency	Temporarily paused screening and enrollment due to COVID-19	4/29/20
Vertex Pharmaceuticals Inc., of Boston	Various drugs	Various indications	Working with clinical trial sites to enable virtual visits and home delivery of study drugs, but is temporarily pausing enrollment in certain studies and may delay some new study starts	3/27/20
Wize Pharma Inc., of Hod Hasharon, Israel	LO2A	Dry eye syndrome in patients with Sjögren's syndrome	Completed dosing of patients in the study; top-line data release may be delayed into third fiscal quarter of 2020 due to COVID-19	5/7/20
X4 Pharmaceuticals Inc., of Cambridge, Mass.	Mavorixafor	WHIM syndrome	Timing of top-line data release delayed from second half of 2021 to 2022 due to COVID-19	5/7/20
Xbrane Biopharma AB, of Solna, Sweden	Xlucane	Wet age-related macular degeneration	Xplore study remains open with 355 of 580 patients enrolled, but COVID-19 makes forecasting future recruitment rate challenging; Biosimilar of Lucentis (ranibizumab)	4/2/20
Xenon Pharmaceuticals Inc., of Burnaby, British Columbia	XEN-1101	Focal epilepsy	X-Tole phase IIb trial is experiencing a significant reduction in new patient enrollment due to COVID-19; top-line data is now expected in the first half of 2021	3/31/20